Agilent Technologies announced that Chris van Ingen, president of its Bio-Analytical Measurement business, will retire on Oct. 31, the last day of Agilent's fiscal year.
Van Ingen, 61, is a 30-year veteran of Agilent and Hewlett-Packard, which spun off Agilent in November 1999. He was appointed to his current position in May 2001.
Agilent did not say who will run the Bio-Analytical Measurement business beginning Nov. 1.
Nektar Therapeutics named former Molecular Devices CFO Tim Harkness senior vice president and chief financial officer.
Harkness, who replaces Louis Drapeau, will receive an annual base salary of $440,000, along with an option to purchase 200,000 shares of common stock, according to a filing with the US Securities and Exchange Commission.
Accelrys announced it has appointed Jeffrey Rodek to its board of directors. Most recently Rodek served as executive chairman of Hyperion Solutions until its acquisition by Oracle earlier this year. From 1999 through 2004, he was chairman and CEO of Hyperion.
He holds a BS in mechanical engineering and an MBA in finance from Ohio State University.
Molecular Insight Pharmaceuticals has appointed Scott Gottlieb to its board. Gottlieb, currently a resident fellow at the American Enterprise Institute, has served as a senior policy maker at the US Food and Drug Administration, most recently as deputy commissioner for Medical and Scientific Affairs. He has also served as a senior official at the Centers for Medicare and Medicaid Services.
Gottlieb holds an MD from the Mount Sinai School of Medicine and a BA in economics from Wesleyan University.